Clinical Trial Update: A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating concurrent stereotactic body radiotherapy with Opdualag in metastatic uveal melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Opdualag (relatlimab and nivolumab)

Snippet

Sponsor: California Pacific Medical Center Research Institute | Conditions: Uveal Melanoma | Phase 2 | Status: UNKNOWN